These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

622 related articles for article (PubMed ID: 26860266)

  • 1. Breakthroughs in the treatment and prevention of Clostridium difficile infection.
    Kociolek LK; Gerding DN
    Nat Rev Gastroenterol Hepatol; 2016 Mar; 13(3):150-60. PubMed ID: 26860266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention and treatment of
    Eliakim-Raz N; Bishara J
    Hum Vaccin Immunother; 2019; 15(6):1453-1456. PubMed ID: 29781761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Berberine blocks the relapse of Clostridium difficile infection in C57BL/6 mice after standard vancomycin treatment.
    Lv Z; Peng G; Liu W; Xu H; Su J
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3726-35. PubMed ID: 25824219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bloom and bust: intestinal microbiota dynamics in response to hospital exposures and Clostridium difficile colonization or infection.
    Vincent C; Miller MA; Edens TJ; Mehrotra S; Dewar K; Manges AR
    Microbiome; 2016 Mar; 4():12. PubMed ID: 26975510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clostridium difficile infection: A brief update on emerging therapies.
    Goldberg EJ; Bhalodia S; Jacob S; Patel H; Trinh KV; Varghese B; Yang J; Young SR; Raffa RB
    Am J Health Syst Pharm; 2015 Jun; 72(12):1007-12. PubMed ID: 26025991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with
    Džunková M; D'Auria G; Xu H; Huang J; Duan Y; Moya A; Kelly CP; Chen X
    Front Cell Infect Microbiol; 2016; 6():119. PubMed ID: 27757389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update of treatment algorithms for Clostridium difficile infection.
    Ooijevaar RE; van Beurden YH; Terveer EM; Goorhuis A; Bauer MP; Keller JJ; Mulder CJJ; Kuijper EJ
    Clin Microbiol Infect; 2018 May; 24(5):452-462. PubMed ID: 29309934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial.
    Gerding DN; Meyer T; Lee C; Cohen SH; Murthy UK; Poirier A; Van Schooneveld TC; Pardi DS; Ramos A; Barron MA; Chen H; Villano S
    JAMA; 2015 May; 313(17):1719-27. PubMed ID: 25942722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential for emerging therapeutic options for Clostridium difficile infection.
    Mathur H; Rea MC; Cotter PD; Ross RP; Hill C
    Gut Microbes; 2014; 5(6):696-710. PubMed ID: 25564777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of refractory or recurrent Clostridium difficile infection].
    Kim SW
    Korean J Gastroenterol; 2012 Aug; 60(2):71-8. PubMed ID: 22926117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clostridium difficile infection in older adults: a review and update on its management.
    Kee VR
    Am J Geriatr Pharmacother; 2012 Feb; 10(1):14-24. PubMed ID: 22260856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.
    Lancaster JW; Matthews SJ
    Clin Ther; 2012 Jan; 34(1):1-13. PubMed ID: 22284993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of Clostridium difficile infection: thinking inside and outside the box.
    Gerding DN; Johnson S
    Clin Infect Dis; 2010 Dec; 51(11):1306-13. PubMed ID: 20979491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clostridium Difficile Colonization in Hematopoietic Stem Cell Transplant Recipients: A Prospective Study of the Epidemiology and Outcomes Involving Toxigenic and Nontoxigenic Strains.
    Jain T; Croswell C; Urday-Cornejo V; Awali R; Cutright J; Salimnia H; Reddy Banavasi HV; Liubakka A; Lephart P; Chopra T; Revankar SG; Chandrasekar P; Alangaden G
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):157-63. PubMed ID: 26211988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in the treatment of Clostridium difficile with fidaxomicin: a narrow spectrum antibiotic.
    Sears P; Ichikawa Y; Ruiz N; Gorbach S
    Ann N Y Acad Sci; 2013 Jul; 1291():33-41. PubMed ID: 23672600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clostridium difficile infection prevention: biotherapeutics, immunologics, and vaccines.
    Gerding DN
    Discov Med; 2012 Jan; 13(68):75-83. PubMed ID: 22284786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and treatment of Clostridium difficile in adults: a systematic review.
    Bagdasarian N; Rao K; Malani PN
    JAMA; 2015 Jan; 313(4):398-408. PubMed ID: 25626036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Oral Fidaxomicin Administration on the Intestinal Microbiota and Susceptibility to Clostridium difficile Colonization in Mice.
    Ajami NJ; Cope JL; Wong MC; Petrosino JF; Chesnel L
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463537
    [No Abstract]   [Full Text] [Related]  

  • 19. Challenges and opportunities in the management of Clostridium difficile infection.
    DuPont HL
    Expert Rev Gastroenterol Hepatol; 2014 Nov; 8(8):863-74. PubMed ID: 25012255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of probiotics in prevention and treatment of patients with Clostridium difficile infection.
    Ollech JE; Shen NT; Crawford CV; Ringel Y
    Best Pract Res Clin Gastroenterol; 2016 Feb; 30(1):111-8. PubMed ID: 27048902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.